{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T09:57:26Z","timestamp":1773655046544,"version":"3.50.1"},"reference-count":2,"publisher":"Australian Centre for Disease Control","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Commun Dis Intell"],"abstract":"<jats:p>The National Neisseria Network (NNN), Australia, comprises reference laboratories in each state and territory that report data on susceptibility profiles for clinical Neisseria gonorrhoeae isolates from each jurisdiction for an agreed group of antimicrobial agents, for the Australian Gonococcal Surveillance Programme (AGSP). The antibiotics are ceftriaxone, azithromycin, ciprofloxacin and penicillin; they represent current or potential agents used for the treatment of gonorrhoea. Ceftriaxone combined with azithromycin is the recommended treatment regimen for gonorrhoea in the majority of Australia. However, there are substantial geographic differences in susceptibility patterns in Australia, with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxycillin, probenecid and azithromycin is recommended for the treatment of gonorrhoea. Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP has a programme-specific quality assurance process.<\/jats:p>","DOI":"10.33321\/cdi.2020.44.73","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T21:02:49Z","timestamp":1600117369000},"source":"Crossref","is-referenced-by-count":0,"title":["Australian Gonococcal Surveillance Programme 1 July to 30 September 2019"],"prefix":"10.33321","volume":"44","author":[{"given":"Monica M","family":"Lahra","sequence":"first","affiliation":[{"name":"The World Health Organisation Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, New South Wales Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW, 2031"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany R","family":"Hogan","sequence":"additional","affiliation":[{"name":"The World Health Organisation Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, New South Wales Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW, 2031"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18788","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Lahra MM, Enriquez RP. Australian Gonococcal Surveillance Programme. Annual Report 2017. Commun Dis Intell (2018). 2018;42. pii: S2209-5081(18)00013-1.","DOI":"10.33321\/cdi.2020.44.4"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Unemo M. Current and future antimicrobial treatment of gonorrhoea \u2013 the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15:364.","DOI":"10.1186\/s12879-015-1029-2"}],"container-title":["Communicable Diseases Intelligence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www1.health.gov.au\/internet\/main\/publishing.nsf\/Content\/AD2DF748753AFDE1CA2584E2008009BA\/$File\/australian_gonococcal_surveillance_programme_1_july_to_30_september_2019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T18:40:07Z","timestamp":1749580807000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojs.cdi.cdc.gov.au\/index.php\/cdi\/article\/view\/111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":2,"URL":"https:\/\/doi.org\/10.33321\/cdi.2020.44.73","archive":["Portico","Portico"],"relation":{},"ISSN":["2209-6051"],"issn-type":[{"value":"2209-6051","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]}}}